IQVIA (IQV) Stock Price, News & Analysis

Company Overview

IQVIA Holdings Inc. is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company helps organizations develop and commercialize therapies by combining data science, real-world evidence and domain expertise. IQVIA’s offerings span the entire product lifecycle, from early-stage clinical development through post-market safety monitoring and commercial optimization.

The company’s clinical development solutions include clinical trial execution, site management, patient recruitment and regulatory affairs support. IQVIA also delivers real-world evidence and analytics through its expansive health information database, drawing on electronic health records, claims data and patient registries. Its technology platforms, such as the Orchestrated Customer Engagement suite and the E360 commercial analytics tool, enable clients to streamline operations, improve decision making and enhance patient engagement.

Operating in over 100 countries, IQVIA serves pharmaceutical, biotechnology, medical device and diagnostic companies, as well as payers and government health agencies. The firm maintains a network of regional offices and research centers across North America, Europe, Asia Pacific, Latin America and the Middle East. This global footprint allows IQVIA to support multi-jurisdictional clinical trials and to deliver localized insights for diverse healthcare markets.

IQVIA was formed in 2016 through the merger of IMS Health, founded in 1954 as a market intelligence provider, and Quintiles, established in 1982 as a contract research organization. Headquartered in Durham, North Carolina, the company is led by Chairman and Chief Executive Officer Ari Bousbib, who has guided its growth into a leading human data science enterprise. Under his leadership, IQVIA continues to invest in next-generation technologies and strategic partnerships to advance innovation in healthcare.

AI Generated. May Contain Errors.

Key Stats

• Today's Range: $155.15 to $158.99
• 50-Day Range: $136.96 to $159.70
• 52-Week Range: $134.65 to $252.88
• Volume: 1.16 million shs
• Average Volume: 1.98 million shs
• Market Capitalization: $27.21 billion
• P/E Ratio: 21.43
• Dividend Yield: N/A
• Price Target: $226.32
• Consensus Rating: Moderate Buy

IQVIA Stock Analysis - MarketRank™

IQVIA scored higher than 97% of companies evaluated by MarketBeat, and ranked 25th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

IQVIA has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 16 buy ratings, 7 hold ratings, and no sell ratings.

Amount of Analyst Coverage

IQVIA has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 12.55%

Earnings Growth

Earnings for IQVIA are expected to grow by 12.55% in the coming year, from $10.84 to $12.20 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of IQVIA is 21.44, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.92.

Price to Earnings Ratio vs. Sector

The P/E ratio of IQVIA is 21.44, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.49.

Price to Earnings Growth Ratio

IQVIA has a PEG Ratio of 1.75. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

IQVIA has a P/B Ratio of 4.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.44% of the float of IQVIA has been sold short.

Short Interest Ratio / Days to Cover

IQVIA has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in IQVIA has recently increased by 29.58%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

IQVIA does not currently pay a dividend.

Dividend Growth

IQVIA does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -0.69

Percentage of Shares Shorted

5.44% of the float of IQVIA has been sold short.

Short Interest Ratio / Days to Cover

IQVIA has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in IQVIA has recently increased by 29.58%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.83

News Sentiment

IQVIA has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 22 news articles for IQVIA this week, compared to 18 articles on an average week.

Search Interest

11 people have searched for IQV on MarketBeat in the last 30 days. This is an increase of 83% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added IQVIA to their MarketBeat watchlist in the last 30 days. This is a decrease of -57% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, IQVIA insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.60% of the stock of IQVIA is held by insiders.

Percentage Held by Institutions

89.62% of the stock of IQVIA is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IQV Stock Analysis - Frequently Asked Questions

How have IQV shares performed this year?

IQVIA's stock was trading at $196.51 at the beginning of the year. Since then, IQV stock has decreased by 20.0% and is now trading at $157.2880.
View the best growth stocks for 2025 here.

How were IQVIA's earnings last quarter?

IQVIA Holdings Inc. (NYSE:IQV) issued its earnings results on Tuesday, May, 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.63 by $0.07. The business's quarterly revenue was up 2.5% on a year-over-year basis.
Read the conference call transcript.

Does IQVIA have any subsidiaries?

IQVIA subsidiaries include Q2 Solutions, Linguamatics, Advanced Health Media LLC, DrugDev, Aileron Solutions, Novella Clinical LLC, 159 Solutions LLC, and more.

How do I buy shares of IQVIA?

Shares of IQV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of IQVIA own?

Based on aggregate information from My MarketBeat watchlists, some other companies that IQVIA investors own include NVIDIA (NVDA), Chevron (CVX), Meta Platforms (META), Bristol Myers Squibb (BMY), Advanced Micro Devices (AMD), Broadcom (AVGO) and McKesson (MCK).

Company Calendar

• Last Earnings: 5/06/2025
• Today: 6/30/2025
• Next Earnings (Estimated): 7/28/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Business Services
• Current Symbol: NYSE:IQV
• CIK: 1478242
• Web: www.iqvia.com
• Phone: (919) 998-2000
• Fax: N/A
• Employees: 86,000
• Year Founded: 2016

Price Target and Rating

• Average Stock Price Target: $226.32
• High Stock Price Target: $276.00
• Low Stock Price Target: $160.00
• Potential Upside/Downside: +43.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 24 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $7.34
• Trailing P/E Ratio: 21.43
• Forward P/E Ratio: 14.51
• P/E Growth: 1.75
• Net Income: $1.37 billion
• Net Margins: 8.61%
• Pretax Margin: 10.66%
• Return on Equity: 29.16%
• Return on Assets: 6.96%

Debt

• Debt-to-Equity Ratio: 2.19
• Current Ratio: 0.82
• Quick Ratio: 0.82

Sales & Book Value

• Annual Sales: $15.41 billion
• Price / Sales: 1.77
• Cash Flow: $16.59 per share
• Price / Cash Flow: 9.48
• Book Value: $33.43 per share
• Price / Book: 4.71

Miscellaneous

• Outstanding Shares: 173,000,000
• Free Float: 170,232,000
• Market Cap: $27.21 billion
• Optionable: Optionable
• Beta: 1.28